SW
CTKB icon

SlateStone Wealth’s Cytek Biosciences CTKB Stock Holding History

SlateStone Wealth’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,967
Closed -$61K – 295
2025
Q2 		$61K Sell
17,967
-1,162
-6% -$3.87K 0.01% 283
2025
Q1 		$77K Buy
19,129
+3,041
+19% +$15.8K 0.01% 278
2024
Q4 		$104K Buy
16,088
+1,193
+8% +$7.11K 0.01% 280
2024
Q3 		$83K Buy
14,895
+2,395
+19% +$13.6K 0.01% 284
2024
Q2 		$70K Buy
+12,500
New +$75.1K 0.01% 276

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SlateStone Wealth's CTKB Position: Q3 2025 in Review

SlateStone Wealth sold out of Cytek Biosciences (CTKB) in Q3 2025, closing a stake of 17,967 shares — an estimated $61K sold.

SlateStone Wealth first reported a position in CTKB in Q2 2024 and held it in 5 quarters. The position peaked at $104K in Q4 2024. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

  • SlateStone Wealth reported no remaining Cytek Biosciences position as of Q3 2025 after selling out during the quarter.
  • SlateStone Wealth sold 17,967 Cytek Biosciences shares in Q3 2025, an estimated $61K.
  • SlateStone Wealth first reported a position in Cytek Biosciences in Q2 2024 and held it in 5 quarters.
  • SlateStone Wealth's Cytek Biosciences position peaked at $104K in Q4 2024.
  • 153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on SlateStone Wealth's 13F filing for Q3 2025, filed 5 Nov 2025.